As an increasing number of orphan drugs are FDA approved, health care payers, employers, and providers are attempting to strike a balance between patient access to innovative treatments and overall affordability. Precision’s Erin Lopata, Christopher Terrone and Ami Gopalan and their co-authors review the results of a PRECISIONvalue and AMCP survey with payer, provider, and employer decision makers about their experiences and activities in the orphan disease space, including tactics to manage affordability of drugs to treat orphan diseases.
Read the full article here!